[go: up one dir, main page]

SG11202100185VA - Treating ulcerative colitis with brazikumab - Google Patents

Treating ulcerative colitis with brazikumab

Info

Publication number
SG11202100185VA
SG11202100185VA SG11202100185VA SG11202100185VA SG11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA SG 11202100185V A SG11202100185V A SG 11202100185VA
Authority
SG
Singapore
Prior art keywords
brazikumab
ulcerative colitis
treating ulcerative
treating
colitis
Prior art date
Application number
SG11202100185VA
Inventor
Carl Gommoll
Aparna Sahoo
Original Assignee
Astrazeneca Collaboration Ventures Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Collaboration Ventures Llc filed Critical Astrazeneca Collaboration Ventures Llc
Publication of SG11202100185VA publication Critical patent/SG11202100185VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202100185VA 2018-07-13 2019-07-11 Treating ulcerative colitis with brazikumab SG11202100185VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862697939P 2018-07-13 2018-07-13
PCT/IB2019/000720 WO2020012244A2 (en) 2018-07-13 2019-07-11 Treating ulcerative colitis with brazikumab

Publications (1)

Publication Number Publication Date
SG11202100185VA true SG11202100185VA (en) 2021-02-25

Family

ID=68072845

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100185VA SG11202100185VA (en) 2018-07-13 2019-07-11 Treating ulcerative colitis with brazikumab

Country Status (11)

Country Link
US (1) US20210277105A1 (en)
EP (1) EP3820897A2 (en)
JP (1) JP2021532176A (en)
KR (1) KR20210032441A (en)
CN (1) CN112689643A (en)
AU (1) AU2019300491A1 (en)
CA (1) CA3105598A1 (en)
EA (1) EA202190197A1 (en)
IL (1) IL279917A (en)
SG (1) SG11202100185VA (en)
WO (1) WO2020012244A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Proteins bind to human IL-23 antigens
CN112807428B (en) * 2020-06-12 2024-08-27 江苏荃信生物医药股份有限公司 Pharmaceutical composition comprising anti-human interleukin 23 monoclonal antibody
EP4623001A1 (en) * 2022-11-22 2025-10-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
TW202540171A (en) 2024-02-06 2025-10-16 美商派拉岡醫療公司 Il-23 antibody compositions and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
PE20000183A1 (en) 1997-07-25 2000-03-11 Schering Corp MAMMAL CYTOKINES AND RELATED REAGENTS
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
BRPI0615018A2 (en) 2005-08-25 2011-04-26 Lilly Co Eli anti-il-23 antibodies, or antigen binding portion thereof, composition containing the same and said use
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
PT2548577T (en) 2005-12-29 2017-05-29 Janssen Biotech Inc Human anti-il-23 antibodies, compositions, methods and uses
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
AR068723A1 (en) 2007-10-05 2009-12-02 Glaxo Group Ltd PROTEIN THAT JOINS ANTIGENS THAT JOINS HUMAN IL-23 AND ITS USES
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MX2011002159A (en) 2008-08-27 2011-03-29 Schering Corp Lyophilized formulatons of engineered anti-il-23p19 antibodies.
EP2414393A1 (en) 2009-04-01 2012-02-08 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
JO3244B1 (en) * 2009-10-26 2018-03-08 Amgen Inc Proteins bind to human IL-23 antigens
PL3295957T3 (en) 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
MX341309B (en) 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies.
MX362039B (en) 2010-11-04 2019-01-07 Boehringer Ingelheim Int Anti-il-23 antibodies.
AP2015008801A0 (en) * 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody

Also Published As

Publication number Publication date
CA3105598A1 (en) 2020-01-16
CN112689643A (en) 2021-04-20
US20210277105A1 (en) 2021-09-09
IL279917A (en) 2021-03-01
EA202190197A1 (en) 2021-04-26
WO2020012244A3 (en) 2020-06-04
EP3820897A2 (en) 2021-05-19
KR20210032441A (en) 2021-03-24
JP2021532176A (en) 2021-11-25
AU2019300491A1 (en) 2021-03-04
WO2020012244A2 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL277514A (en) Methods of treating ulcerative colitis
IL256279A (en) Crispr/cas9-based treatments
PL3552652T5 (en) Catheter devices with valves
IL279917A (en) Treating ulcerative colitis with brazikumab
GB201608885D0 (en) Treatment
GB202009845D0 (en) Flood vent with panel
IL275553A (en) Surfboard with overlap
IL255092A0 (en) Combination treatments with seribantumab
IL256109A (en) Methods of treating or preventing a proteopathy
IL272738A (en) Treatment regimens
IL266292A (en) Treatment regimens
PL3580182T3 (en) Water treatment
HK40050836A (en) Treating ulcerative colitis with brazikumab
GB201609851D0 (en) Water treatment
ZAA201801118S (en) Baths
ZAA201801111S (en) Baths
ZA201804726B (en) Water treatment facility
ZA201706977B (en) Water treatment
GB201722126D0 (en) Jacuzzis / baths
GB201708860D0 (en) ZoneFeeder with zoneLock
PT3239415T (en) Tap with case
ZA201702594B (en) Water treatment
TWM534100U (en) Metal-plastic co-structure with nano-waterproof function
GB201614273D0 (en) Diving boards
AU201614884S (en) Tub